8-K: Zevra Therapeutics Reports FY 2024 Financial Results and Sells PRV for $150 Million

Zevra Therapeutics announces its fourth quarter and full year 2024 financial results, highlighted by $23.6 million in net revenue for the year and the sale of a Priority Review Voucher for $150 million.

Summary

• Zevra Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company achieved $23.6 million in net revenue for FY 2024, driven by record product net revenue of $10.2 million during Q4 2024.
• A key highlight was the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million.
• The company initiated the commercial launch of MIPLYFFA following FDA approval on September 20, 2024, and achieved U.S. commercial availability on November 21, 2024.
• As of December 31, 2024, Zevra received 109 total prescription enrollment forms for MIPLYFFA.
• OLPRUVA had 4 new patient enrollments during Q4 2024.
• The company is targeting the second half of 2025 for filing the Marketing Authorisation Application with the European Medicines Agency (EMA) for MIPLYFFA.
• Eight additional patients enrolled in the Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS), bringing the total patients enrolled to 27.
• Net loss for 2024 was ($105.5) million, or ($2.28) per basic and diluted share, compared to a net loss of ($46.0) million, or ($1.30) per basic and diluted share for 2023.
• As of December 31, 2024, cash, cash equivalents and investments were $75.5 million.
• The company forecasts its cash runway extends into 2029, based on current operating forecasts and anticipated revenue streams.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strong revenue growth, the PRV sale, and the extended cash runway. However, the increased net loss and ongoing R&D expenses temper the overall outlook.

Positives

• Zevra achieved $23.6 million in net revenue for FY 2024.
• The sale of the PRV for $150 million strengthens the company's financial position.
• The commercial launch of MIPLYFFA is underway, with $10.1 million in net revenue for FY 2024.
• The company's cash runway is forecasted to extend into 2029.
• The company received 109 total prescription enrollment forms for MIPLYFFA as of Dec. 31, 2024.

Negatives

• The company reported a net loss of ($105.5) million for 2024, significantly higher than the ($46.0) million loss in 2023.
• Cost of Goods Sold was $13.7 million, including $6.2 million of non-cash intangible asset amortization, and $5.7 million in inventory obsolescence reserve expense related to OLPRUVA inventory during the year.
• Operating Expense was $97.0 million, which includes non-cash stock compensation expense of $14.9 million, of which $2.4 million was accelerated vesting related to severance arrangements, and severance expense of $2.7 million which was recognized as part of both R&D and SG&A expenses during the year.

Risks

• The forward-looking statements are subject to several known and unknown uncertainties, risks, and other important factors that may cause actual results, performance, or achievements to be materially different.
• The PRV sale is subject to conditions and may not close in the timeframe expected or at all.
• The company's future performance depends on the successful commercialization of MIPLYFFA and OLPRUVA.
• The company is still loss making and dependent on future sales and milestones to achieve profitability.

Future Outlook

Based on current operating forecasts, existing resources extend the company's cash runway into 2029. This forecast includes anticipated net revenue from MIPLYFFA and OLPRUVA sales, net reimbursements from the French EAP for arimoclomol, royalties under the AZSTARYS license agreement, and continued investments into the development pipeline.

Management Comments

• Neil F. McFarlane, Zevra's President and Chief Executive Officer, stated that 2024 was a transformational year for Zevra and that the company is starting 2025 from a position of strength.
• He also mentioned that their priorities are guided by Zevra's strategic plan, categorized under four actionable pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.

Industry Context

Zevra's focus on rare diseases aligns with a growing trend in the pharmaceutical industry, where companies are increasingly targeting niche markets with high unmet needs. The sale of the PRV highlights the value of rare disease designations and the potential for significant returns on investment in this sector.

Comparison to Industry Standards

• Comparing Zevra to other small-cap rare disease companies, the $150 million PRV sale is a significant event that provides substantial non-dilutive funding.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics, which focus on rare genetic diseases, have achieved significant market capitalization through successful commercialization of their therapies.
• Zevra's success will depend on its ability to effectively commercialize MIPLYFFA and OLPRUVA, as well as advance its pipeline of product candidates.

Stakeholder Impact

• Shareholders will benefit from the increased cash position due to the PRV sale.
• Patients with rare diseases will have access to new therapies like MIPLYFFA.
• Employees will benefit from the company's continued growth and investment in its pipeline.

Next Steps

• Zevra will participate in a fireside chat at the 37th Annual ROTH Conference on March 17, 2025.
• The company is targeting the second half of 2025 for filing the Marketing Authorisation Application with the European Medicines Agency (EMA) for MIPLYFFA.
• Zevra will continue to focus on commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.

Key Dates